Idiopathic pulmonary fibrosis (IPF) is an irreversible lung disease, in which the cells in the lung tissue surrounding the air sacs begin to die, as a result of which oxygen entering the bloodstream reduces, causing functional damage. Risk factors for the disease include smoking, exposure to certain types of dust, viral infection, gastroesophageal reflux disease and environmental concerns such as pollution. Since the disease is fatal, a lung transplant is a sought after treatment option while certain anti-inflammatory drugs and immunosuppressants slow down the impairment process. Factors driving the growth of the IPF diagnostic and treatment market are rising healthcare expenditure, growth in ageing population, burgeoning number of smokers and a healthy product pipeline for IPF therapy. Geographically the United States is expected to be the largest market for Idiopathic pulmonary fibrosis followed by Europe.
This section provides an anatomy of the research process followed for calculating market size and forecasts along with a list of the secondary data sources used and the primary inputs which were taken for data validation. It also provides an outline of the various segmentations which have been covered as part of the report.
Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Industry Overview
In this section, the entire Idiopathic Pulmonary Fibrosis market is explained along with the causes, diagnosis, and prevention of the disease, the various drivers, restraints and opportunities to the market and the prevalence of the disease based on age, gender and region. A product pipeline of various drugs and vaccines for IPF therapy have been mentioned along with innovations in the market. Certain regulations specific to the industry are also listed out, followed by a detailed scenario analysis.
Europe Middle East and Africa
Middle East and Africa
This Section deals with major players in the market, their market shares, products, growth strategies, financials, and recent investments among others. Key industry players in the Idiopathic pulmonary fibrosis treatment market are Roche, Boehringer Ingelheim, AdAlta and Aeolus Pharmaceuticals among others.